Boehringer Ingelheim is the latest large drugmaker to challenge the U.S. government over Medicare’s new power to negotiate prices of select top-selling medicines, filing a 62-page lawsuit Friday in federal district court.
Like other pharmaceutical companies that have sued to block the drug price program, Boehringer claims it violates the U.S. Constitution and unfairly compels drugmakers to accept terms set by the government.
Merck & Co., Bristol Myers Squibb, Astellas Pharma and Johnson & Johnson have each filed separate lawsuits in various district courts, along with the powerful industry lobbying groups PhRMA and the Chamber of Commerce. Reuters first reported Boehringer’s suit Monday.
